Home Compare HIK.L vs WST
Stock Comparison · Structural lead, mixed market

Hikma Pharmaceuticals vs West Pharmaceutical Services: Which Stock Looks Stronger in 2026?

The structural profiles are close, with West Pharmaceutical Services carrying a narrow edge on valuation. Hikma Pharmaceuticals still has the edge on valuation, which keeps the comparison from looking entirely one-sided. On the market side, West Pharmaceutical Services is in better shape — its trend is intact while Hikma Pharmaceuticals's trend has broken down. That puts structure and market broadly in agreement — West Pharmaceutical Services's lead looks more confirmed than conflicted.

The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (HIK.L: STOXX 600, WST: Russell 1000).

Updated 2026-05-17

The page question resolves through valuation, where Hikma Pharmaceuticals PLC holds the stronger read even though the broader score still favours West Pharmaceutical Services, Inc..

Trajectory Similarity
0.71
Similar
Peer-set rank: #13
within Hikma Pharmaceuticals PLC's functional peer set

This pair is matched through long-term financial trajectory similarity within the selected peer universe.

The pair sits on a clearly comparable long-term path, though it is not a near-twin match.

The strongest overlap appears in revenue stability and capital structure.

Similarity drivers
revenue stabilitycapital structure
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
HIK.L
Hikma Pharmaceuticals PLC
60
Peer-Score
Signal qualityMedium
Peer basis: STOXX 600
vs
WST
West Pharmaceutical Services, Inc.
62
Peer-Score
Signal qualitylow
Peer basis: Russell 1000

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: HIK.L vs WST Profitability 45 71 Stability 33 37 Valuation 87 50 Growth 67 91 HIK.L WST
Gap Ranking
#1 Valuation +37
#2 Profitability +26
#3 Growth +24
#4 Stability +4
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for HIK.L and WST Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer HIK.LWST Relative valuation Structural strength

West Pharmaceutical Services, Inc. occupies the cheaper side of the setup map, although Hikma Pharmaceuticals PLC still holds the stronger structural profile.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Valuation
Both profiles are strong on valuation, but Hikma Pharmaceuticals PLC leads clearly.
Profitability
On profitability, the edge is clear — both rank well, but West Pharmaceutical Services, Inc. sits noticeably higher.
Valuation — Dominant Gap
HIK.L
87
WST
50
Gap+37in favour of HIK.L

The main spread comes from a meaningfully cheaper peer-relative valuation.

What keeps the gap from being one-sided

Hikma Pharmaceuticals PLC still shows lower market-fundamental divergence, which keeps the wider picture mixed rather than completely one-sided.

What this means for the comparison

Valuation is the clearest driver of the lead, with profitability adding further support — though valuation still provides a real counterweight.

Explore full peer positioning in AssetNext

Break down the HIK.L vs WST comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how HIK.L and WST each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.